N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A

被引：2
|
作者：
Chowdary, Pratima [1 ]
机构：
[1] Royal Free Hosp, Katharine Dormandy Haemophilia & Thrombosis Ctr, Pond St, London NW3 2QG, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2020年 / 18卷
关键词：
D O I：
10.1111/jth.14966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
    Ducore, Jonathan M.
    Miguelino, Maricel G.
    Powell, Jerry S.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 559 - 571
  • [22] Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
    Chowdary, Pratima
    Poulsen, Lone Hvitfeldt
    Escobar, Miguel A.
    Kearney, Susan
    Chitlur, Meera B.
    Klamroth, Robert
    Misgav, Mudi
    Negrier, Claude
    Clausen, Wan Hui Ong
    Driessler, Frank
    Landorph, Andrea
    Santagostino, Elena
    BLOOD, 2018, 132
  • [23] Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product
    Ehrlich, Veronika
    Leidenmuehler, Peter
    Dietrich, Barbara
    Hoebarth, Gerald
    Ruthsatz, Tanja
    Turecek, Peter L.
    Wolfsegger, Martin
    Weber, Alfred
    Gritsch, Herbert
    Hoellriegl, Werner
    Turecek, Marietta
    BLOOD, 2016, 128 (22)
  • [24] N8-GP - a new long-acting factor VIII for the treatment of patients with haemophilia A
    Ehrenforth, Silke
    HAEMOPHILIA, 2014, 20 : 188 - 188
  • [25] Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies
    Di Minno, Matteo Nicola Dario
    Minno, Alessandro Di
    Calcaterra, Ilenia
    Cimino, Ernesto
    Dell'Aquila, Francesco
    Franchini, Massimo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (02): : 253 - 255
  • [26] Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies
    Di Minno, Matteo Nicola Dario
    Di Minno, Alessandro
    Calcaterra, Ilenia
    Cimino, Ernesto
    Dell'Aquila, Francesco
    Franchini, Massimo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (01): : 32 - 42
  • [27] Factor VIII half-life and clinical characteristics of severe hemophilia A.
    van Dijk, K
    van der Born, JG
    Mauser-Bunschoten, EP
    Roosendaal, G
    Lenting, PJ
    de Groot, PG
    van den Berg, HM
    BLOOD, 2004, 104 (11) : 844A - 844A
  • [28] Evaluation of long-term prophylaxis with a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A
    Abbuehl, Brigitt
    Engl, Werner
    Patrone, Lisa
    Prener, Anne
    HAEMOPHILIA, 2016, 22 : 108 - 108
  • [29] Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations
    Bukkems, Laura H.
    Preijers, Tim
    van Spengler, Max W. F.
    Leebeek, Frank W. G.
    Cnossen, Marjon H.
    Mathot, Ron A. A.
    THROMBOSIS AND HAEMOSTASIS, 2021, 121 (06) : 731 - 740
  • [30] Switch to extended half-life recombinant factor VIII FC in severe hemophilia A patients under prophylaxis. Experience in one centre
    Jimenez, R.
    Nunez, R.
    Jimenez, P.
    Rodriguez-Martorell, F. J.
    Perez-Simon, J. A.
    HAEMOPHILIA, 2018, 24 : 117 - 117
12345